Table 3

Characteristics of identified neoantigen-specific T cell responses in TIL infusion products

Gene mutationWT peptideMutant peptideFrequency (% multimer+CD8+ T cells of total CD8+ T cells)Restriction element
Patient 3RBM12 S>LSPHEAGFCVLPHEAGFCV29.00HLA-B*51:01
VARS T>MEVADEATGALEVADEAMGAL0.096HLA-A*25:01
MYLK G>VEVFPEDTGTYEVFPEDTVTY1.90HLA-A*25:01
LRP3 T>SLTAARPSQTVLLTAARPSQSVL0.039HLA-A*25:01
WDR1 N>KDSFAGKGHTNDSFAGKGHTK0.50HLA-A*68:01
Patient 4TTC37 A>VYLDGKAVDYYLDGKVVDY1.14HLA-A*01:01
ENTPD4 P>LATDTNNPNVNYATDTNNLNVNY3.35HLA-A*01:01
MAB21L1 V>MLRIRDRYVVLRIRDRYVM0.007HLA-B*08:01
Patient 8RAD51AP1-002 S>FKVKSPVEKKKVKFPVEKK0.195HLA-A*03:01
  • TIL, tumor infiltrating lymphocyte.